Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications.

Published in: JCO precision oncology (2024)

Biomarker-based patient selection and rational combinations show promise in expanding the use of PARP inhibitors.

Keyphrases